Clinical trials: Staphylococcus Aureus Infections
Bacterial Pneumonia
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
- Trial name
- ATTAIN1 (NCT00107952)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 761 people
- Sponsor
- Cumberland Pharmaceuticals
Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections
PMT for MDRO Decolonization
This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant…
- Conditions
- Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection
- Trial name
- NCT05632315
- Testing
- PMT
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Pennsylvania
Staphylococcal Infections, Joint Prosthesis
StaphVAX Immunogenicity in Orthopedic Implant Patients
S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein.
- Trial name
- NCT00211926
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Skin Infections, Bacterial
Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA
The purpose of this study is to provide further evidence of the clinical and bacteriological efficacy of retapamulin in the treatment of subjects with SITL or impetigo due to MRSA.
- Trial name
- NCT00852540
- Testing
- Retpamulin Ointment, 1%, Linezolid
- Where
- 53 sites in United States
- Volunteers
- 410 people
- Sponsor
- Stiefel, a GSK Company
Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection, Bone and Joint Infection
Pristinamycin in the Treatment of MSSA Bone and Joint Infection
Staphylococcus aureus represents the leading pathogen implicated in bone and joint infection (BJI), usually requiring prolonged combination antimicrobial therapy, which may be particularly challenging in the case of MDR bacteria…
- Trial name
- NCT03177343
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Hospices Civils de Lyon
Bacteremia
Virulence Determinants in S Aureus Bacteremia
The purpose of this study is to investigate why some people develop life-threatening infections caused by the bacteria Staphylococcus aureus, while other people do not.
- Trial name
- NCT00319826
- Testing
- No intervention
- Where
- United States
- Volunteers
- 1,354 people, healthy volunteers welcome
- Sponsor
- Duke University
Staphylococcal Bacteraemia
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with…
- Trial name
- NCT04775953
- Testing
- Cefazolin, Dalbavancin, Daptomycin
- Where
- 24 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Skin Infection
Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus
Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA.
- Trial name
- CG400549 (NCT01593761)
- Testing
- CG400549
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- CrystalGenomics, Inc.
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Staphylococcal Infection, Abscess
Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections
The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).
- Conditions
- Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
- Trial name
- NCT00352612
- Testing
- clindamycin, cephalexin
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Aaron Chen
Severe Sepsis
Platelet-associated Inflammation in Severe Sepsis
Sepsis represents a serious public health issue characterized by a complex inflammatory response. In addition to their hemostatic role, platelets display inflammatory functions by secreting a variety of immunomodulatory factors…
- Trial name
- PlatISSep (NCT03029039)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Osteomyelitis, Methicillin-resistant Staphylococcus Aureus
Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis
The primary question of this study is to understand if trimethoprim-sulfamethoxazole (TMP-SMX) is as effective as vancomycin for treating methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis.
- Trial name
- NCT00324922
- Testing
- trimethoprim-sulfamethoxazole, vancomycin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Washington
Bacteremia
Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives
Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform, two…
- Trial name
- NCT01184339
- Testing
- MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
- Volunteers
- 1,165 people
- Sponsor
- MicroPhage, Inc.
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus
Penicillin Against Flucloxacillin Treatment Evaluation
There is theroretical superiority with benzylpenicillin over orther anti-staphylococcal penicillins (ASP) for treatment of penicillin susceptible S.
- Trial name
- PANFLUTE (NCT03632642)
- Testing
- Benzylpenicillin, Flucloxacillin
- Where
- Australia
- Sponsor
- The University of Queensland
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Surgical Site Infection
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
The purpose of this study is to see whether applying povidone iodine (PVI) to the noses of patients undergoing lower extremity (leg, ankle, or foot) orthopedic fixation procedures of high-energy lower extremity fractures (HELEF)…
- Trial name
- POTENT (NCT05763602)
- Testing
- povidone-iodine topical ointment
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Loreen Herwaldt
Nosocomial Infections
Effect of Metallic Nanoparticles on Nosocomial Bacteria
This research aims to study the properties of metallic nanoparticles"MNPs" (silver nanoparticles "AgNps" and copper nanoparticles "CuNps") on the 2 most common nosocomial bacteria which are highly resistant to antibiotics…
- Trial name
- NCT04775238
- Testing
- Silver nanoparticles, Copper nanoparticles
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Pneumonia
Ceftobiprole in the Treatment of Patients With Community-Acquired Pneumonia
The purpose of this study is to compare the clinical cure rate (ratio of clinically cured patients to the total number of patients) of ceftobiprole medocaril versus a comparator in the treatment of patients with…
- Trial name
- NCT00326287
- Testing
- Ceftobiprole medocaril, Ceftriaxone with or without Linezolid
- Volunteers
- 638 people
- Sponsor
- Basilea Pharmaceutica
Staphylococcus Aureus
S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues
Surgical site infections (SSI) are a significant clinical issue that requires the use of a great amount of resources. In particular, periprosthetic joint infections (PJIs) have potentially catastrophic effects on patients'…
- Trial name
- NCT04666532
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Rothman Institute Orthopaedics